Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • Log out
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Quantitative Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting Brain and Testis Penetration of Xenobiotic Compounds

Junichi Enokizono, Hiroyuki Kusuhara, Atsushi Ose, Alfred H. Schinkel and Yuichi Sugiyama
Drug Metabolism and Disposition June 2008, 36 (6) 995-1002; DOI: https://doi.org/10.1124/dmd.107.019257
Junichi Enokizono
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroyuki Kusuhara
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Atsushi Ose
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alfred H. Schinkel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuichi Sugiyama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The role of breast cancer resistance protein (BCRP/ABCG2) in limiting the brain and testis penetration of xenobiotic compounds in the blood-brain and -testis barriers was investigated using Bcrp–/– mice. Tissue/plasma concentration ratios in the brain (Kp,brain) and testis (Kp,testis) obtained under steady-state conditions were significantly increased in Bcrp–/– mice for PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine), N-hydroxyl PhIP, MeIQx (2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline), dantrolene, and prazosin. In addition, the Kp,brain of triamterene and the Kp,testis of 4′-hydroxyl PhIP were also significantly increased in Bcrp–/– mice. The effect of functional impairment of Bcrp on the brain uptake of PhIP, dantrolene, and daidzein in Bcrp–/– mice determined using in situ brain perfusion was weaker than that observed on the Kp values. In vitro transcellular transport experiments using cell lines expressing mouse Bcrp or P-glycoprotein (Mdr1a/Abcb1a) showed that, among the tested Bcrp substrates, PhIP, MeIQx, prazosin, and triamterene are common substrates of Bcrp and P-glycoprotein. The Kp values of common substrates exhibited a smaller increase both in the brain and testis of Bcrp–/– mice than expected from the in vitro Bcrp activities. The Bcrp-specific substrates were weak acids, whereas basic or neutral BCRP substrates were also P-glycoprotein substrates. These results suggest that BCRP limits the tissue penetration of xenobiotic compounds in the blood-brain and -testis barriers, but its in vivo importance is also modulated by P-glycoprotein activity.

The brain and testis are highly protected from the invasion of xenobiotic compounds by the blood-brain barrier (BBB) and blood-testis barrier (BTB). The BBB is formed by brain microvascular endothelial cells, whereas myoid and Sertoli cells are involved in the BTB in addition to the endothelial cells (Bart et al., 2002; Kusuhara and Sugiyama, 2005; Scherrmann, 2005). In addition to the highly developed tight junctions between adjacent cells, the BBB and BTB express multiple xenobiotic transporters characterized by broad substrate specificities. They actively extrude xenobiotic compounds into the circulating blood and, thereby, limit tissue penetration from the circulating blood. On the luminal side of the BBB, ABC transporters, such as P-glycoprotein (P-gp/MDR1/ABCB1), multidrug resistance-associated protein 1 (MRP1/ABCC1) and -4 (MRP4/ABCC4), and breast cancer resistance protein (BCRP/ABCG2), are expressed (Schinkel, 1999; Leggas et al., 2004; Lee et al., 2005; Leslie et al., 2005; Scherrmann, 2005). Among them, P-gp is the best characterized transporter providing a barrier function for the BBB. Cumulative studies have shown that it plays a key role in limiting the penetration of a variety of drugs and toxins (Schinkel, 1999; Scherrmann, 2005). Immunohistochemical analysis has demonstrated the expression of P-gp, MRP1, and BCRP in the BTB (Bart et al., 2004; Augustine et al., 2005). In vivo studies using Mdr1a–/– or Mrp1–/– mice have shown their roles in protecting the testis from invasion by their substrates (Wijnholds et al., 1998; Uhr et al., 2000).

The present study is focused on BCRP in the BBB and BTB. BCRP is a member of the ABC G-transporter family (Kusuhara and Sugiyama, 2007). Cumulative in vivo studies, particularly using Bcrp–/– mice, have shown the importance of BCRP in limiting oral absorption and mediating the biliary and urinary excretion of xenobiotic compounds (Jonker et al., 2002; van Herwaarden et al., 2003; Mizuno et al., 2004; Adachi et al., 2005; Kondo et al., 2005; Ando et al., 2007). The functional role of BCRP in the BBB was first demonstrated by Breedveld et al. (2005), who showed that the brain distribution of imatinib was significantly increased in Bcrp–/– mice, although subsequent analysis showed that P-gp plays a significant role in limiting brain penetration of imatinib rather than Bcrp (Bihorel et al., 2007). Recently, we reported for the first time that BCRP limits the penetration of phytoestrogens, such as daidzein, genistein, and coumestrol, into the brain and testis (Enokizono et al., 2007b). On the other hand, there was no difference in the brain distribution of other BCRP substrates, such as dehydroepiandrosterone sulfate (DHEAS), mitoxantrone, pitavastatin, and fluoroquinolones, between wild-type and Bcrp–/– mice (Hirano et al., 2005; Lee et al., 2005; Ando et al., 2007). These results emphasize the difficulties in predicting in vivo relevance from in vitro transport assays.

The purpose of the present study is to determine the quantitative relationship between the transport activities of the compounds by mouse Bcrp and the increase in their tissue/plasma concentration ratios. Adachi et al. (2001) and Yamazaki et al. (2001) previously demonstrated that the corrected flux ratio (CFR), obtained by the ratio of the basal-to-apical and apical-to-basal transport across the monolayers of epithelial cells expressing P-gp divided by the corresponding ratio in mock cells, is a good predictor of in vivo P-gp activity at the BBB (Adachi et al., 2001; Yamazaki et al., 2001). In addition to phytoestrogens (Enokizono et al., 2007b), we investigated the effect of BCRP on the brain and testicular distribution of five compounds, including dietary carcinogens MeIQx and PhIP and drugs (dantrolene, prazosin, and triamterene), using Bcrp–/– mice. Transcellular transport of the compounds across the monolayers of MDCK cells expressing mouse Bcrp was also determined. The CFR for Bcrp was not a good predictor of the increase in Kp values in the brain and testis in Bcrp–/– mice. It was also found that some Bcrp substrates, particularly those exhibiting a marginal increase in Kp values, are also P-gp substrates. The present study proposes that Bcrp plays a significant role in limiting the tissue penetration of xenobiotic compounds, but the impact of functional impairment of Bcrp is also modulated by P-glycoprotein activity on their shared substrates.

Materials and Methods

Materials and Animals. MeIQx and PhIP were purchased from Wako Pure Chemicals (Osaka, Japan), and dantrolene, prazosin, and triamterene were purchased from Sigma-Aldrich (St. Louis, MO). 4′-Hydroxyl PhIP (4′-OH PhIP) was a gift from Dr. Hitoshi Nakagama (Biochemistry Division, National Cancer Center Research Institute, Tokyo, Japan). All other chemicals were commercially available and of reagent grade. Male wild-type FVB mice and Bcrp–/– mice (Jonker et al., 2002) used in the present study were 13 to 19 weeks old and weighed 23 to 35 g. All animals were maintained at a controlled temperature with a 12-h light/dark cycle. Food and water were available ad libitum.

In Vivo Study with Continuous Infusion. Under urethane anesthesia (1.25 g/kg i.p.), the right jugular vein of the mice was cannulated with a polyethylene tube (PE-10; BD Biosciences, Franklin Lakes, NJ). Compounds were administered via the cannula by continuous infusion for 120 or 150 min. Blood samples were collected from the left jugular vein at appropriate time points and centrifuged at 4°C and 10,000g for 5 min to obtain plasma. Immediately after the last blood sampling, mice were sacrificed by cervical dislocation, and the brain and testes were collected and homogenized with 4 volumes of phosphate-buffered saline (PBS) to obtain a 20% homogenate. Plasma samples and tissue homogenates were stored at –80°C until use. The concentrations of the parent forms were measured using LC/MS for all the compounds except PhIP. For PhIP, the concentrations of two hydroxylated metabolites [4′-OH PhIP and N-hydroxyl PhIP (N-OH PhIP)] were also measured in addition to that of the parent form. Kp,brain and Kp,testis were obtained by dividing the brain and testis concentrations by the plasma concentrations at the last sampling point (Adachi et al., 2001).

In Situ Brain Perfusion. In situ brain perfusion was carried out according to the previous report by Dagenais et al. (2000). Briefly, mice were anesthetized by i.p. injection of pentobarbital sodium (50 mg/kg), and the right common carotid artery was catheterized with a polyethylene tube (PE-10) mounted on a 30-gauge needle. Before insertion of the catheter, the common carotid artery was ligated caudally. During surgery, the body temperature was maintained on a heated plate. The syringe containing the perfusion fluid was placed in an infusion pump (PerkinElmer Life and Analytical Sciences, Meriden, CT) and connected to the catheter. Before perfusion, the thorax of the animal was opened, the heart was cut, and perfusion was started immediately at a flow rate of 1 ml/min. The perfusion fluid consisted of Krebs-Henseleit bicarbonate buffer: 25 mM NaHCO3, 118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.2 mM NaH2PO4, 1.2 mM CaCl2, and 10 mM d-glucose. The perfusion fluid was gassed with 95% O2 and 5% CO2 for pH control (7.4) and warmed to 37°C in a water bath. The concentration of the test compounds was 5 μM. The 1-min perfusion was terminated by decapitation. The brain was then removed, and the cortex of the right cerebral hemisphere was collected and weighed.

Calculation of Initial Uptake Clearance. The average vascular volume (Vvasc) following brain perfusion is reported to be 10 μl/g brain (Dagenais et al., 2000). This value was used to correct for vascular contamination in brain tissue. The initial uptake clearances of test compounds (CLup, microliters per minute per gram of brain) were calculated using the equation CLup = Xbrain/T/Cperf, where Xbrain is the compound in the right cortex (nanomoles per gram of brain) corrected for vascular contamination (Xtotal – Vvasc × Cperf), Cperf is the concentration of compound in the perfusate (nanomoles per microliter), and T is the perfusion time (minutes).

In Vitro Transport Study. In vitro transport experiments of mouse Bcrp were performed as previously reported with minor modifications (Matsushima et al., 2005). Briefly, MDCK II cells were seeded into a 24-well Transwell (Corning, Cambridge, MA) at a density of 1.4 × 105 cells/well and grown for 3 days in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA) with 10% fetal bovine serum (Sigma-Aldrich) and 1% antibiotic-antimycotic solution (Sigma-Aldrich). The cells were infected with the recombinant adenovirus harboring green fluorescent protein (GFP) or mouse Bcrp expression vector at a 200 multiplicity of infection. The details of the construction of these recombinant adenoviruses are described in a previous report (Kondo et al., 2004). After a 2-day culture, both GFP- and Bcrp-expressing cells (MDCK II/GFP and MDCK II/Bcrp, respectively) were used for transport studies. The cells were preincubated in Krebs-Henseleit bicarbonate (pH 7.4) buffer for 30 min, and transport experiments were initiated by replacing the medium on one side of the cell monolayer with Krebs-Henseleit buffer containing 3 μM test compounds. At appropriate times (20, 40, and 60 min), 100-μl aliquots were taken from the opposite side of the cell monolayer and replaced with 100 μl of buffer. In vitro transport experiments of mouse Mdr1a were carried out using Mdr1a-expressing LLC-PK1 cells (L-Mdr1a). L-Mdr1a and parent LLC-PK1 cells were seeded in a 24-well Transwell at a density of 4.8 × 105 cells/well and grown in medium 199 (Invitrogen) with 10% fetal bovine serum and 1% antibiotic-antimycotic solution. Medium was changed on the 2nd day, and cells were subjected to the transport study on the 4th day. The procedures for the transport study were the same as those used for mouse Bcrp.

Efflux rates were calculated from the slopes of the time profiles of the apical-to-basal and basal-to-apical transport. Flux ratios were obtained by dividing efflux rates in the basal-to-apical direction by those in the apical-to-basal direction. Flux ratios in transporter-expressing cells were divided by those in control cells to give a CFR. CFR was used as the transport activity index.

Preparation ofN-OH PhIP. After the administration of PhIP to rats, N-OH PhIP is excreted into the bile mainly in its glucuronide form (Dietrich et al., 2001). Therefore, N-OH PhIP was purified from β-glucuronidase-treated bile obtained from rats that had been given PhIP. Under ether anesthesia, the bile duct was cannulated with a polyethylene tube (PE-10), then PhIP was i.p. administered at a dose of 100 mg/kg, and bile was collected for 2.5 h. Bile was loaded onto a solid-phase extraction cartridge (OASIS HLB; Waters, Milford, MA), which was then washed with water and eluted with acetonitrile. The eluted solution was evaporated, reconstituted in PBS containing 5 mM ascorbic acid, and treated with β-glucuronidase (Roche Diagnostics, Basel, Switzerland) for 3 h at 37°C. Ascorbic acid was added to prevent the autooxidation of N-OH PhIP. The reaction was stopped by adding a 30% volume of acetonitrile, and N-OH PhIP was purified by HPLC, using a D-7000 series instrument (Hitachi, Tokyo, Japan) equipped with an Inertsil ODS-2, 5 μm, 4.6-mm i.d. × 250-mm column (GL Science, Tokyo, Japan). The mobile phase A was 10 mM ammonium acetate, and the mobile phase B was acetonitrile. The mobile phase B concentration was 7% at 0 min and was then linearly increased to 20% over 60 min followed by a 5-min re-equilibration with the initial concentration. The flow rate was 1.2 ml/min, the column temperature was 40°C, and the detector wavelength was 313 nm. Under these conditions, PhIP and N-OH PhIP were eluted at 38.2 and 31.1 min, respectively. The purified N-OH PhIP was used to construct standard curves for the quantification of N-OH PhIP concentrations in plasma, brain, and testis.

Quantification. Plasma samples were diluted with PBS to obtain 20% diluted plasma. This diluted plasma and 20% tissue homogenate were precipitated with 3 volumes of acetonitrile and centrifuged at 4°C, 15,000g, for 10 min. The supernatants were evaporated, reconstituted in mobile phase, and subjected to LC/MS/(MS) analysis. Aliquots obtained from in vitro transport studies were mixed with an equal volume of acetonitrile and centrifuged at 4°C and 15,000g for 10 min. The supernatants were diluted with an appropriate volume of mobile phase and subjected to LC/MS/(MS) analysis. PhIP, 4′-OH PhIP, and N-OH PhIP were analyzed in multireaction monitoring mode using an API2000 instrument (Applied Biosystems, Foster City, CA) equipped with an Agilent 1100 series LC system (Agilent Technologies, Palo Alto, CA), and the other compounds were analyzed in selected ion monitoring mode using a ZQ Micromass instrument equipped with an Alliance 2695 system (Waters) or LCMS-2010 EV equipped with a Prominence LC system (Shimadzu, Kyoto, Japan). The analytical columns used were a CAPCELL PAK C18 MG 3 μm, 3-mm i.d. × 35 mm (Shiseido, Kanagawa, Tokyo) for the analysis of PhIP and its metabolites and CAPCELL PAK C18 MG 3 μm, 2-mm i.d. × 50 mm for the other compounds. The column temperature was 40°C. Detailed LC conditions and mass-to-charge ratios are shown in Table 1.

View this table:
  • View inline
  • View popup
TABLE 1

Analytical conditions in LC/MS/(MS) analysis

Statistical Analysis. Statistical analysis of significant differences was performed using the two-tailed Student's t test. A probability of <0.05 was considered to be statistically significant.

Results

Effects of Bcrp on the Brain and Testis Distribution at Steady State. Compounds were administered by continuous infusion to obtain tissue distribution data under steady-state conditions. In the case of PhIP, the plasma and tissue concentrations of its two metabolites, 4′-OH PhIP and N-OH PhIP, were also determined. The time courses of the plasma concentrations are shown in Fig. 1. The plasma concentrations of PhIP, 4′-OH PhIP, and prazosin were significantly lower in Bcrp–/– mice at several time points. The Kp values are shown in Fig. 2. Both the Kp,brain and Kp,testis values were significantly increased in Bcrp–/– mice in comparison with those in wild-type mice for PhIP, N-OH PhIP, MeIQx, dantrolene, and prazosin. For 4′-OH PhIP, the brain concentrations of 4′-OH PhIP were below the limit of quantification (15 nM) in both wild-type and Bcrp–/– mice, whereas Kp,testis exhibited a significant increase in Bcrp–/– mice. For triamterene, both the Kp,brain and Kp,testis values were increased in Bcrp–/– mice; however, only the increase in the Kp,brain was statistically significant.

Effect of Bcrp on Uptake Transport in the BBB. The effect of functional impairment of Bcrp on the brain uptake was investigated by the in situ brain perfusion technique for PhIP, dantrolene, and daidzein. In all cases, a relatively large increase in the Kp,brain values was observed in Bcrp–/– mice. Significant increases in CLup were observed in Bcrp–/– mice for dantrolene and daidzein (Fig. 3). The increase was 2.1-fold for dantrolene and 1.4-fold for daidzein. The CLup of PhIP was not significantly changed in Bcrp–/– mice.

In Vitro Transport by Mouse Bcrp and Mdr1a and a Comparison with in Vivo Data. Transcellular transport of the compounds was examined in polarized cell lines expressing Bcrp and Mdr1a where Bcrp and Mdr1a are localized in the apical membrane (Yamazaki et al., 2001; Matsushima et al., 2005). In Bcrp-expressing cells, all the test compounds exhibited directional transport with statistically significant changes in the permeability (Fig. 4; Table 2), indicating that all the compounds are Bcrp substrates. The comparison between Kp ratios and CFR values in Bcrp-expressing cells is shown in Fig. 5 and Table 3. The data of three phytoestrogens were taken from our previous study (Enokizono et al., 2007b). The relationships did not show any positive correlation (Fig. 5). Although PhIP, MeIQx, prazosin, and triamterene exhibited large CFR values, the effect of functional impairment of Bcrp on the tissue concentration was marginal.

View this table:
  • View inline
  • View popup
TABLE 2

Transcellular transport of the test compounds across the monolayers of polarized cell lines expressing mouse Bcrp or Mdr1a and their corresponding control cells

Data were taken from Figs. 4 and 6. Permeabilities were obtained from the slopes of the transcellular transport from 40 to 120 min and the concentration in the donor compartment.

View this table:
  • View inline
  • View popup
TABLE 3

Comparison among Kp ratios, in vitro transport profiles, and pKa values

The time profiles in the transcellular transport in Mdr1a-expressing cells are shown in Fig. 6 and Table 2. In Mdr1a-expressing cells, directional transport across the cell monolayers was clearly enhanced for MeIQx, PhIP, and prazosin, and apical-to-basal transport was significantly reduced for triamterene (Table 2). No significant change was observed for dantrolene (Table 2). Therefore, MeIQx, PhIP, prazosin, and triamterene are Mdr1a substrates, whereas dantrolene is not. PhIP, MeIQx, prazosin, and triamterene, which exhibited a marginal increase in the Kp ratios, were all common substrates of Bcrp and Mdr1a, whereas dantrolene and the phytoestrogens with a larger increase in the Kp ratios were Bcrp-specific substrates. The most acidic and basic pKa values are shown in Table 3. The four BCRP-selective compounds were all weak acids, whereas the other compounds were basic or neutral at physiological pH.

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Plasma concentration-time profiles in wild-type and Bcrp–/– mice during continuous infusion. Compounds were administered by continuous infusion at infusion rates of 20 μmol/h/kg for PhIP, 2 μmol/h/kg for MeIQx, 1 μmol/h/kg for dantrolene, 2 μmol/h/kg for prazosin, and 1 μmol/h/kg for triamterene. The plasma concentrations of the compounds in wild-type and Bcrp–/– mice are represented by closed and open symbols, respectively. Each symbol with a bar represents the mean value and S.E. obtained from three or four mice. Asterisks represent statistically significant differences between wild-type and Bcrp–/– mice: *, P < 0.05 and **, P < 0.01.

Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.

Comparison of the brain and testicular distributions between wild-type and Bcrp–/– mice. Tissue/plasma concentration ratios (Kp values) were obtained in both the brain and testis at the end of infusion. The Kp values in wild-type and Bcrp–/– mice are represented by closed and open bars, respectively. Each bar with an error bar represents the mean value and S.E. obtained from three or four mice. Asterisks represent statistically significant differences between wild-type and Bcrp–/– mice: *, P < 0.05 and **, P < 0.01.

Discussion

In the present study, the effects of BCRP on the brain and testicular distribution of two dietary carcinogens and three drugs were investigated using Bcrp–/– mice. The increase in the Kp values in the brain and testis in Bcrp–/– mice compared with wild-type mice indicates that Bcrp limits both the brain and testicular distribution of MeIQx, PhIP, N-OH PhIP, dantrolene, and prazosin. For triamterene, the Kp,brain was significantly increased in Bcrp–/– mice, whereas the Kp,testis was increased, but this was not statistically significant. For 4′-OH PhIP, Kp,testis was significantly increased in Bcrp–/– mice, whereas its brain concentration was below the limit of quantification; thus, the impact of functional impairment of Bcrp on the Kp,brain of 4-OH PhIP remains to be evaluated. In contrast, the impact of functional impairment of Bcrp on the uptake transport in the BBB was smaller than that observed on the Kp values (Fig. 3). Because the Kp values determined under steady-state conditions represent the ratio of the clearance of uptake transport to that of efflux transport, it is likely that Bcrp mainly influences the efflux transport of its substrates in the BBB. The increase in the Kp,brain of prazosin in Bcrp–/– mice is consistent with a previous study in which the brain concentration of prazosin was increased by coadministration of GF120918 in Mdr1a–/– mice (Cisternino et al., 2004). The present results on PhIP contradict a previous study in which neither Kp,brain nor Kp,testis was changed (van Herwaarden et al., 2003). This discrepancy can be explained by the difference in the method of determining the plasma and tissue concentrations. van Herwaarden et al. (2003) determined the total radioactivities in the plasma and tissues without separation, whereas in the present study, the parent drug and metabolites were separately determined by LC/MS/MS. Indeed, the total radioactivity associated with plasma specimens was mainly associated with unknown metabolites, other than the metabolites 4′-OH and N-OH PhIP, when 14C-PhIP was given to mice (data not shown). It is possible that the metabolites in the plasma made it difficult to detect an increase in the brain and testicular distribution of PhIP in Bcrp–/– mice.

Fig. 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 3.

Comparison of the uptake clearances (CLup) in the BBB between wild-type and Bcrp–/– mice. The brain uptake for 1 min was determined by the in situ brain perfusion technique. CLup was obtained by subtracting the amount associated with the capillary space from that associated with brain specimens divided by the concentration in the infusate. CLup values in wild-type and Bcrp–/– mice are represented by closed and open bars, respectively. Each bar with an error bar represents the mean value and S.E. obtained from three or four mice. Asterisks represent statistically significant differences between wild-type and Bcrp–/– mice: *, P < 0.05 and **, P < 0.01.

Fig. 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 4.

Transcellular transport across MDCKII cell monolayers expressing GFP (MDCKII/GFP) or mouse Bcrp (MDCKII/Bcrp). The transcellular transport of test compounds (3 μM) in the apical-to-basal (circles) and basal-to-apical directions (triangles) was compared between MDCKII/GFP (closed symbols with dotted line) and MDCKII/Bcrp cells (open symbols and solid line). Each symbol with a bar represents the mean value and S.E. of triplicate experiments.

The in vivo Bcrp activities (expressed as Kp ratios) were compared with the in vitro transport activities by Bcrp (expressed as CFR) estimated using a cell line expressing mouse Bcrp. Previously, Adachi et al. (2001) and Yamazaki et al. (2001) demonstrated clear positive relationships between the Kp ratios and CFR for Mdr1a. Unlike the case of Mdr1a, the in vivo and in vitro Bcrp activities did not show a positive relationship. The Bcrp substrates with a greater CFR exhibited a somewhat smaller increase in Kp values (Fig. 5). We assumed that this discrepancy is accounted for by the difference in the contribution of Bcrp to the net efflux at the BBB and BTB. Indeed, it was found that some Bcrp substrates are also P-gp substrates. In particular, the compounds exhibiting large increases in Kp ratios were Bcrp-specific substrates. Therefore, it is likely that, for common substrates of Bcrp and P-gp, the impact of functional impairment of Bcrp on the Kp values becomes smaller than predicted from the CFR because of active efflux mediated by P-gp. This will also account for the discrepancy reported previously that the brain distribution of some Bcrp substrates, such as fluoroquinolones, mitoxantrone, and pitavastatin, was unchanged in Bcrp–/– mice (Hirano et al., 2005; Lee et al., 2005; Ando et al., 2007). All these compounds are also substrates of P-gp (de Lange et al., 2000; Yagi et al., 2003; Sasabe et al., 2004; Hirano et al., 2005), and the brain distributions of mitoxantrone, grepafloxacin, and ulifloxacin were significantly increased in Mdr1a/1b–/– mice (Yagi et al., 2003; Sasabe et al., 2004). As far as DHEAS is concerned, the CLup of DHEAS in the brain was not increased in Mdr1a/1b–/– mice (Lee et al., 2005). The reason for the absence of a change in the Kp,brain in Bcrp–/– remains unknown. It is possible that brain perfusion study was not suitable for the detection of the involvement of Bcrp in the transport of DHEAS. It is also possible that other transporters besides Bcrp and P-gp are involved in the transport of DHEAS in the BBB. A candidate transporter is MRP4, which is expressed on the luminal side of BMECs (Leggas et al., 2004) since DHEAS is a substrate of MRP4 (Bai et al., 2004).

Fig. 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 5.

Relationships between the in vitro transport activities and in vivo BCRP effects on the brain and testicular distribution. The transport activities of test compounds were estimated from the study using MDCK II cell monolayers expressing mouse Bcrp and expressed as CFRs. In vivo BCRP activities were evaluated by the ratio of Kp values in wild-type and Bcrp–/– mice. Kp ratios were plotted against CFR. 1, PhIP; 2, MeIQx; 3, dantrolene; 4, prazosin; 5, triamterene; 6, daidzein; 7, genistein; 8, coumestrol. Kp values and CFR of phytoestrogens were obtained from Enokizono et al. (2007b).

The four Bcrp-specific substrates are weak acids, whereas the other compounds are basic or neutral at physiological pH (Table 3). P-gp is well characterized by its preferential substrate recognition of lipophilic and basic compounds. BCRP also recognizes basic compounds, such as cimetidine and imatinib (Burger et al., 2004; Breedveld et al., 2005), but it also accepts acidic compounds, such as methotrexate and sulfate conjugates (Volk et al., 2002; Suzuki et al., 2003). Based on the substrate specificity, it would be speculated that BCRP plays a major role in the efflux of acidic compounds in the BBB and BTB, but only a limited role in the efflux of basic compounds, which are mainly extruded by P-gp. It should be noted that some MRPs have been identified in the BBB, which accepts anionic compounds as substrates (Kusuhara et al., 1998; Zhang et al., 2000; Leggas et al., 2004). Further studies are necessary to elucidate the role of Bcrp in the BBB.

Dietary carcinogens, such as PhIP, 2-amino-3-methylimidazo[4,5-f]quinoline, and 3-amino-1,4-dimethyl-5H-pyrido[4,3-b]indole, have been identified as BCRP substrates (van Herwaarden et al., 2006), and MeIQx was identified as a BCRP substrate for the first time in the present study. Schinkel and his collaborators (van Herwaarden et al., 2003, 2006; Jonker et al., 2005) demonstrated the involvement of BCRP in the oral availability, milk secretion, biliary, and intestinal excretion of dietary carcinogens. In addition, the present study revealed that BCRP limits penetration of dietary carcinogens into the brain and testis. N-Hydroxylation is a bioactivation pathway for dietary carcinogens (Kim and Guengerich, 2005). Our results suggest that Bcrp accepts N-OH PhIP; moreover, BCRP may limit DNA adduct formation in the brain and testis.

The plasma concentrations of PhIP, 4′-OH PhIP, and prazosin were slightly, but significantly, lower in Bcrp–/– mice, suggesting induction of some clearance mechanisms for these substrates in Bcrp–/– mice. Previously, we reported the induction of compensatory mechanisms for the elimination of troglitazone sulfate from the systemic circulation in Bcrp–/– mice (Enokizono et al., 2007a). The underlying mechanisms remain unknown. Further studies are required to investigate such compensatory mechanisms in Bcrp–/– mice.

In conclusion, the present study revealed that BCRP limits the brain and testicular distribution of MeIQx, PhIP, prazosin, triamterene, and dantrolene. Because of the overlapping substrate specificities of Bcrp and P-gp, P-gp is also involved in the efflux of some Bcrp substrates at the BBB, thereby modulating the impact of functional impairment of BCRP.

Fig. 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 6.

Transcellular transport across the monolayers of parent LLC-PK1 cells and LLC-PK1 expressing mouse Mdr1a (L-Mdr1a). The transcellular transport of test compounds (3 μM) in the apical-to-basal (circles) and basal-to-apical directions (triangles) was compared between parent LLC-PK1 cells (closed symbols with dotted line) and L-Mdr1a cells (open symbols and solid line). Each symbol with a bar represents the mean value and S.E. of triplicate experiments.

Acknowledgments

We thank Hitoshi Nakagama (Biochemistry Division, National Cancer Center Research Institute) for supplying 4′-OH PhIP and Junko Iida and Futoshi Kurotobi (Shimadzu) for technical support of the LC/MS system.

Footnotes

  • This study was supported by Grants-in-Aid for Scientific Research (A) from Japan Society for the Promotion of Science (JSPS) (KAKENHI 17209005 for Y.S.) and for Scientific Research (B) (KAKENHI 18390046 for H.K.) from Japan Society for the Promotion of Science.

  • Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.

  • doi:10.1124/dmd.107.019257.

  • ABBREVIATIONS: BBB, blood-brain barrier; BTB, blood-testis barrier; ABC, ATP-binding cassette; P-gp, P-glycoprotein; MDR (Mdr in mice), multidrug resistance protein; MRP (Mrp in mice), multidrug resistance-associated protein; BCRP (Bcrp in mice), breast cancer resistance protein; DHEAS, dehydroepiandrosterone sulfate; CFR, corrected flux ratio; MeIQx, 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline; PhIP, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine; 4′-OH PhIP, 4′-hydroxyl PhIP; PBS, phosphate-buffered saline; LC/MS, liquid chromatography/mass spectrometry; N-OH PhIP, N-hydroxyl PhIP; Kp,brain, brain/plasma concentration ratio; Kp,testis, testis/plasma concentration ratio; GFP, green fluorescent protein; LC/MS/(MS), liquid chromatography (tandem) mass spectrometry.

    • Received October 12, 2007.
    • Accepted February 27, 2008.
  • The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    Adachi Y, Suzuki H, Schinkel AH, and Sugiyama Y (2005) Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen. Mol Pharmacol 67: 923–928.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Adachi Y, Suzuki H, and Sugiyama Y (2001) Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharmacol Res 18: 1660–1668.
    OpenUrlCrossRef
  3. ↵
    Ando T, Kusuhara H, Merino G, Alvarez AI, Schinkel AH, and Sugiyama Y (2007) Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones. Drug Metab Dispos 35: 1873–1879.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Augustine LM, Markelewicz RJ, Jr., Boekelheide K, and Cherrington NJ (2005) Xenobiotic and endobiotic transporter mRNA expression in the blood-testis barrier. Drug Metab Dispos 33: 182–189.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Bai J, Lai L, Yeo HC, Goh BC, and Tan TM (2004) Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione. Int J Biochem Cell Biol 36: 247–257.
    OpenUrlCrossRefPubMed
  6. ↵
    Bart J, Groen HJ, van der Graaf WT, Hollema H, Hendrikse NH, Vaalburg W, Sleijfer DT, and de Vries EG (2002) An oncological view on the blood-testis barrier. Lancet Oncol 3: 357–363.
    OpenUrlCrossRefPubMed
  7. ↵
    Bart J, Hollema H, Groen HJ, de Vries EG, Hendrikse NH, Sleijfer DT, Wegman TD, Vaalburg W, and van der Graaf WT (2004) The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours. Eur J Cancer 40: 2064–2070.
    OpenUrlCrossRefPubMed
  8. ↵
    Bihorel S, Camenisch G, Lemaire M, and Scherrmann JM (2007) Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier. J Neurochem 102: 1749–1757.
    OpenUrlCrossRefPubMed
  9. ↵
    Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, and Schellens JH (2005) The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 65: 2577–2582.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G, and Nooter K (2004) Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104: 2940–2942.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Cisternino S, Mercier C, Bourasset F, Roux F, and Scherrmann JM (2004) Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res 64: 3296–3301.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Dagenais C, Rousselle C, Pollack GM, and Scherrmann JM (2000) Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J Cereb Blood Flow Metab 20: 381–386.
    OpenUrlPubMed
  13. ↵
    de Lange EC, Marchand S, van den Berg D, van der Sandt IC, de Boer AG, Delon A, Bouquet S, and Couet W (2000) In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin. Eur J Pharm Sci 12: 85–93.
    OpenUrlCrossRefPubMed
  14. ↵
    Dietrich CG, de Waart DR, Ottenhoff R, Bootsma AH, van Gennip AH, and Elferink RP (2001) Mrp2-deficiency in the rat impairs biliary and intestinal excretion and influences metabolism and disposition of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo. Carcinogenesis 22: 805–811.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Enokizono J, Kusuhara H, and Sugiyama Y (2007a) Involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect. Drug Metab Dispos 35: 209–214.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Enokizono J, Kusuhara H, and Sugiyama Y (2007b) Role of breast cancer resistance protein (Bcrp/Abcg2) in the disposition of phytoestrogens: the importance of Bcrp in the efflux transport in the blood-brain and -testis barriers. Mol Pharmacol 72: 967–975.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, and Sugiyama Y (2005) Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 68: 800–807.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink RP, Rosing H, et al. (2002) The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 99: 15649–15654.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Jonker JW, Merino G, Musters S, van Herwaarden AE, Bolscher E, Wagenaar E, Mesman E, Dale TC, and Schinkel AH (2005) The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med 11: 127–129.
    OpenUrlCrossRefPubMed
  20. ↵
    Kim D and Guengerich FP (2005) Cytochrome P450 activation of arylamines and heterocyclic amines. Annu Rev Pharmacol Toxicol 45: 27–49.
    OpenUrlCrossRefPubMed
  21. ↵
    Kondo C, Onuki R, Kusuhara H, Suzuki H, Suzuki M, Okudaira N, Kojima M, Ishiwata K, Jonker JW, and Sugiyama Y (2005) Lack of improvement of oral absorption of ME3277 by prodrug formation is ascribed to the intestinal efflux mediated by breast cancer resistant protein (BCRP/ABCG2). Pharmacol Res 22: 613–618.
    OpenUrlCrossRef
  22. ↵
    Kondo C, Suzuki H, Itoda M, Ozawa S, Sawada J, Kobayashi D, Ieiri I, Mine K, Ohtsubo K, and Sugiyama Y (2004) Functional analysis of SNPs variants of BCRP/ABCG2. Pharmacol Res 21: 1895–1903.
    OpenUrlCrossRef
  23. ↵
    Kusuhara H and Sugiyama Y (2005) Active efflux across the blood-brain barrier: role of the solute carrier family. NeuroRx 2: 73–85.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Kusuhara H and Sugiyama Y (2007) ATP-binding cassette, subfamily G (ABCG family). Pflugers Arch 453: 735–744.
    OpenUrlCrossRefPubMed
  25. ↵
    Kusuhara H, Suzuki H, Naito M, Tsuruo T, and Sugiyama Y (1998) Characterization of efflux transport of organic anions in a mouse brain capillary endothelial cell line. J Pharmacol Exp Ther 285: 1260–1265.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Lee YJ, Kusuhara H, Jonker JW, Schinkel AH, and Sugiyama Y (2005) Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein. J Pharmacol Exp Ther 312: 44–52.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Leggas M, Adachi M, Scheffer GL, Sun D, Wielinga P, Du G, Mercer KE, Zhuang Y, Panetta JC, Johnston B, et al. (2004) Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 24: 7612–7621.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Leslie EM, Deeley RG, and Cole SP (2005) Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204: 216–237.
    OpenUrlCrossRefPubMed
  29. ↵
    Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, and Sugiyama Y (2005) Identification of the Hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther 314: 1059–1067.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Mizuno N, Suzuki M, Kusuhara H, Suzuki H, Takeuchi K, Niwa T, Jonker JW, and Sugiyama Y (2004) Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice. Drug Metab Dispos 32: 898–901.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Sasabe H, Kato Y, Suzuki T, Itose M, Miyamoto G, and Sugiyama Y (2004) Differential involvement of multidrug resistance-associated protein 1 and P-glycoprotein in tissue distribution and excretion of grepafloxacin in mice. J Pharmacol Exp Ther 310: 648–655.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    Scherrmann JM (2005) Expression and function of multidrug resistance transporters at the blood-brain barriers. Expert Opin Drug Metab Toxicol 1: 233–246.
    OpenUrlCrossRefPubMed
  33. ↵
    Schinkel AH (1999) P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 36: 179–194.
    OpenUrlCrossRefPubMed
  34. ↵
    Suzuki M, Suzuki H, Sugimoto Y, and Sugiyama Y (2003) ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem 278: 22644–22649.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Uhr M, Steckler T, Yassouridis A, and Holsboer F (2000) Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 22: 380–387.
    OpenUrlCrossRefPubMed
  36. ↵
    van Herwaarden AE, Jonker JW, Wagenaar E, Brinkhuis RF, Schellens JH, Beijnen JH, and Schinkel AH (2003) The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Res 63: 6447–6452.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    van Herwaarden AE, Wagenaar E, Karnekamp B, Merino G, Jonker JW, and Schinkel AH (2006) Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. Carcinogenesis 27: 123–130.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    Volk EL, Farley KM, Wu Y, Li F, Robey RW, and Schneider E (2002) Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res 62: 5035–5040.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    Wijnholds J, Scheffer GL, van der Valk M, van der Valk P, Beijnen JH, Scheper RJ, and Borst P (1998) Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage. J Exp Med 188: 797–808.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Yagi Y, Shibutani S, Hodoshima N, Ishiwata K, Okudaira N, Li Q, Sai Y, Kato Y, and Tsuji A (2003) Involvement of multiple transport systems in the disposition of an active metabolite of a prodrug-type new quinolone antibiotic, prulifloxacin. Drug Metab Pharmacokinet 18: 381–389.
    OpenUrlCrossRefPubMed
  41. ↵
    Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M, and Lin JH (2001) In vitro substrate identification studies for P-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther 296: 723–735.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    Zhang Y, Han H, Elmquist WF, and Miller DW (2000) Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells. Brain Res 876: 148–153.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 36 (6)
Drug Metabolism and Disposition
Vol. 36, Issue 6
1 Jun 2008
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Quantitative Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting Brain and Testis Penetration of Xenobiotic Compounds
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Quantitative Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting Brain and Testis Penetration of Xenobiotic Compounds

Junichi Enokizono, Hiroyuki Kusuhara, Atsushi Ose, Alfred H. Schinkel and Yuichi Sugiyama
Drug Metabolism and Disposition June 1, 2008, 36 (6) 995-1002; DOI: https://doi.org/10.1124/dmd.107.019257

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Quantitative Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting Brain and Testis Penetration of Xenobiotic Compounds

Junichi Enokizono, Hiroyuki Kusuhara, Atsushi Ose, Alfred H. Schinkel and Yuichi Sugiyama
Drug Metabolism and Disposition June 1, 2008, 36 (6) 995-1002; DOI: https://doi.org/10.1124/dmd.107.019257
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Human ADME Properties of Abrocitinib
  • MSCs Pharmacokinetics under liver diseases
  • In Vitro P450 Suppression by Peptide Not Observed in Clinic
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics